Table 3. The interrelationships between the clinicopathological characteristics of patients with breast cancer, Src kinase family member expression and Ki67.

Total patient cohort (274 patients)		χ2 P-values
Variables	Numbers	c-Src nuc	c-Src cyto	c-Src memb	Lyn nuc	Lyn cyto	Lyn memb	Lck nuc	Lck cyto	Lck memb	Ki 67
Age (<50/>50 years)	68/206	0.786	0.638	0.798	0.259	0.027	0.297	0.639	0.927	0.024	0.965
Tumour type (duct/lob/tub/others)	260/9/2/3	0.788	0.431	0.446	0.642	0.547	0.492	0.375	0.032	0.842	0.360
Grade (G1/G2/G3)	20/122/132	0.021	0.001	0.017	0.019	0.632	0.991	0.034	0.543	0.741	0.006
Size (<20, 20–50, >50 mm)	111/148/15	0.421	0.037	0.007	0.029	0.832	0.115	0.892	0.580	0.926	0.186
Lymph node (positive/negative)	132/142	0.732	0.359	0.589	0.123	0.200	0.247	0.957	0.308	0.311	0.590
ER status (positive/negative)	180/94	0.043	<0.001 a	0.006 a	0.133	0.122	0.876	0.001 a	0.600	0.118	0.997
PgR status (positive/negative)	132/140	0.184	0.002 a	0.001 a	0.339	0.015	0.048	0.097	0.036	0.090	0.280
HER2 status (positive/negative)	38/236	0.007	<0.001	0.007	0.733	0.836	0.772	0.168	0.085	1.000	0.200

Abbreviations: c-Src=total Src kinase; c-Src cyto=c-Src cytoplasmic expression; c-Src memb=c-Src membrane expression; c-Src nuc=c-Src nuclear expression; duct=ductal carcinoma; ER=oestrogen receptor; Grade=Bloom and Richardson grade; HER2=human epidermal growth factor receptor 2; Ki67=Ki67 proliferation score, low <5, moderate 5–20, high >20; Lck cyto=Lck cytoplasmic expression; Lck memb=Lck membrane expression; Lck nuc=Lyn nuclear expression; lob=lobular carcinoma; Lyn cyto=Lyn cytoplasmic expression; Lyn memb=Lyn membrane expression; Lyn nuc=Lyn nuclear expression; others=mucinous, mucoid and micropapillary carcinoma; tub=tubular carcinoma.

^aNegative correlation.

Bold typeface is used to highlight significant P-values.